The impact of viability assessment using cardiac MRI and echocardiogram on the outcome of revascularization in patients with multi-vessels coronary artery disease and moderate to severe ischemic cardiomyopathy

References

1. 1.↵
   1. Bhandari B,
   2. Quintanilla Rodriguez BS,
   3. Masood W. Ischemic Cardiomyopathy

   . Treasure Island (FL): StatPearls Publishing; 2022.
2. 2.
   1. Cleaveland Clinic

   . Ischemic Cardiomyopathy What is ischemic cardiomyopathy? [Updated 2018 July 12; Accessed 2021 Jul 6]. Available at: https://my.clevelandclinic.org/health/diseases/17145-ischemic-cardiomyopathy
3. 3.↵
   Mayo Clinic. Coronary artery disease - symptoms and causes. Overview. [Updated 2022 May 25; Accessed 2021 Jul 6]. Available at: https://www.mayoclinic.org/diseases-conditions/coronary-artery-disease/symptoms-causes/syc-20350613
4. 4.↵
   Centers for Disease Control and Prevention. Heart Disease Facts. [Updated 2022 October 14; Accessed 2021 Jul 6]. Available at: https://www.cdc.gov/heartdisease/facts.htm
5. 5.↵
   1. Aljefree N,
   2. Ahmed F.

   Prevalence of cardiovascular disease and associated risk factors among adult population in the gulf region: A systematic review. Adv Public Health 2015; 2015.
6. 6.↵
   1. Al-Nozha MM,
   2. Arafah MR,
   3. Al-Mazrou YY,
   4. Al-Maatouq MA,
   5. Khan NB,
   6. Khalil MZ, et al.

   Coronary artery disease in Saudi Arabia. Saudi Med J 2004; 25: 1165–1171.

   OpenUrlPubMed
7. 7.↵
   1. Jiménez Borreguero LJ,
   2. Ruiz-Salmerón R.

   Assessment of Myocardial Viability in Patients Before Revascularization. Rev Esp Cardiol 2003; 56: 721–733.

   OpenUrlPubMed
8. 8.↵
   1. Hunold P,
   2. Jakob H,
   3. Erbel R,
   4. Barkhausen J,
   5. Heilmaier C.

   Accuracy of myocardial viability imaging by cardiac MRI and PET depending on left ventricular function. World J Cardiol2018; 10: 110–118.

   OpenUrlPubMed
9. 9.↵
   1. Panza JA,
   2. Ellis AM,
   3. Al-Khalidi HR,
   4. Holly TA,
   5. Berman DS,
   6. Oh JK, et al.

   Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med 2019; 381: 739–748.

   OpenUrlPubMed
10. 10.↵
    1. Beanlands RS,
    2. Nichol G,
    3. Huszti E,
    4. Humen D,
    5. Racine N,
    6. Freeman M, et al.

    F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007; 50: 2002–2012.

    OpenUrlFREE Full Text
11. 11.
    1. Haas F,
    2. Haehnel CJ,
    3. Picker W,
    4. Nekolla S,
    5. Martinoff S,
    6. Meisner H, et al.

    Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997; 30: 1693–1700.

    OpenUrlFREE Full Text
12. 12.↵
    1. Eitzman D,
    2. al-Aouar Z,
    3. Kanter HL,
    4. vom Dahl J,
    5. Kirsh M,
    6. Deeb GM, et al.

    Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992; 20: 559–565.

    OpenUrlFREE Full Text
13. 13.↵
    Diabetes & Revascularization Procedures to Restore Blood Flow. Society for cardiovascular angiography and intervention. [Updated 2014 Mar 9; Accessed 2021 Aug 4]. Available at: http://www.secondscount.org/treatments/treatments-detail-2/diabetes-revascularization-procedures-to-restore-b#.YHHwF8rXehD
14. 14.↵
    1. Patel H,
    2. Mazur W,
    3. Williams Sr KA,
    4. Kalra DK.

    Myocardial viability–state of the art: is it still relevant and how to best assess it with imaging? Trends Cardiovasc Med 2018; 28: 24–37.

    OpenUrl
15. 15.↵
    1. Kandolin RM,
    2. Wiefels CC,
    3. Mesquita CT,
    4. Chong AY,
    5. Boland P,
    6. Glineur D, et al.

    The current role of viability imaging to guide revascularization and therapy decisions in patients with heart failure and reduced left ventricular function. Can J Cardiol 2019; 35: 1015–1029.

    OpenUrl
16. 16.↵
    1. Löffler AI,
    2. Kramer CM.

    Myocardial viability testing to guide coronary revascularization. Interv Cardiol Clin 2018; 7: 355–365.

    OpenUrl
17. 17.↵
    1. Di Carli MF,
    2. Maddahi J,
    3. Rokhsar S,
    4. Schelbert HR,
    5. Bianco-Batlles D,
    6. Brunken RC, et al.

    Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 1998; 116: 997–1004.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Auerbach MA,
    2. Schoder H,
    3. Hoh C,
    4. Gambhir SS,
    5. Yaghoubi S,
    6. Sayre JW, et al.

    Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999; 99: 2921–2926.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Allman KC,
    2. Shaw LJ,
    3. Hachamovitch R,
    4. Udelson JE.

    Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39: 1151–1158.

    OpenUrlFREE Full Text
20. 20.↵
    1. Howlett JG,
    2. Stebbins A,
    3. Petrie MC,
    4. Jhund PS,
    5. Castelvecchio S,
    6. Cherniavsky A, et al.

    CABG improves outcomes in patients with ischemic cardiomyopathy: 10-year follow-up of the STICH trial. JACC Heart Fail 2019; 7: 878–887.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Serdar CC,
    2. Cihan M,
    3. Yücel D,
    4. Serdar MA.

    Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies. Biochem Med (Zagreb) 2021; 31: 010502.

    OpenUrl